Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ieq Capital LLC

Ieq Capital LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,838 shares of the biopharmaceutical company’s stock after selling 1,496 shares during the quarter. Ieq Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $2,734,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. Private Advisor Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.0% in the third quarter. Private Advisor Group LLC now owns 5,361 shares of the biopharmaceutical company’s stock worth $5,635,000 after acquiring an additional 303 shares in the last quarter. Silver Oak Securities Incorporated increased its holdings in Regeneron Pharmaceuticals by 523.5% during the 3rd quarter. Silver Oak Securities Incorporated now owns 929 shares of the biopharmaceutical company’s stock worth $969,000 after purchasing an additional 780 shares during the last quarter. Ballentine Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 4.9% in the 3rd quarter. Ballentine Partners LLC now owns 1,062 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 50 shares in the last quarter. Elwood & Goetz Wealth Advisory Group LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $517,000. Finally, Allworth Financial LP boosted its stake in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. Allworth Financial LP now owns 709 shares of the biopharmaceutical company’s stock valued at $745,000 after buying an additional 48 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on REGN. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $700.33 on Friday. The company has a 50-day moving average price of $699.40 and a two-hundred day moving average price of $882.47. The stock has a market cap of $76.56 billion, a price-to-earnings ratio of 18.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.